Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
11.2M
-
Number of holders
-
52
-
Total 13F shares, excl. options
-
31.2M
-
Shares change
-
+6.21M
-
Total reported value, excl. options
-
$205M
-
Value change
-
+$41.7M
-
Number of buys
-
36
-
Number of sells
-
-11
-
Price
-
$6.56
Significant Holders of Ikena Oncology, Inc. - Common Stock, $0.001 par value (IKNA) as of Q2 2023
56 filings reported holding IKNA - Ikena Oncology, Inc. - Common Stock, $0.001 par value as of Q2 2023.
Ikena Oncology, Inc. - Common Stock, $0.001 par value (IKNA) has 52 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 31.2M shares
.
Largest 10 shareholders include FMR LLC (5.07M shares), Atlas Venture Life Science Advisors, LLC (5.02M shares), ORBIMED ADVISORS LLC (3.19M shares), BVF INC/IL (3.17M shares), Omega Fund Management, LLC (2.25M shares), CHI Advisors LLC (2.12M shares), Artal Group S.A. (1.85M shares), Avoro Capital Advisors LLC (1.64M shares), BlackRock Inc. (1.27M shares), and VANGUARD GROUP INC (1.1M shares).
This table shows the top 52 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.